胃癌术后腹腔热灌注联合全身化疗的临床应用

为研究胃癌术后腹腔热灌注化疗联合全身化疗的治疗效果。对140例胃癌根治术后患者随机分为腹腔热灌注化疗组(n=72)和全身化疗组(n=68)。腹腔热灌注化疗组患者在全身化疗同时应用腹腔热灌注化疗,观察两组术后并发症、不良反应、术后生存率及腹腔复发率。两组在术后并发症及不良反应差异无统计学意义。腹腔热灌注化疗组和全身化疗组术后3、5年生存率分别为86.1%(62/72)、60.2%(41/68)和58.3%(42/72)、29.4%(20/68)(P<0.05)。腹腔热灌注化疗组和全身化疗组术后3、5年腹腔复发率分别为5.6%(4/72)、27.8%(19/68)和20.6%(15/72)、53%(36/68),差异有统计学意义,P<0.05。初步研究结果提示,胃癌术后腹腔热灌注联合全身化疗可有效控制肿瘤的复发和转移,提高胃癌术后患者的生存率。

Clinical application of postoperative intraperitoneal hyperthermic perfusion combined with venoclysis for gastric cancer

To study the effect of intraperitoneal hyperthermic perfusion chemotherapy combined with venoclysis on postoperative gastric cancer. A total of 140 postoperative patients with gastric cancer were divided into IPHPC group (n=72)and chemotherapy of venoclysis group (n=68). The intraperitoneal hyperthermic perfusion chemotherapy and chemotherapy of venoclysis were applied for the patients in IPHPC group at one time. Postoperative complications, toxicity, survival rate and peritoneal recurrence rate in the two groups were observed. There was no significant difference in the postoperative complications and toxicity between the two groups. The 3-5-year survival rates were 86.1%, 61.1% and 58.3%, 29.4% in IPHPC group and CV group. The 3-5-year peritoneal cavity recurrence rates were 5.6%, 20.6% and 27.8%, 53% in IPHPC group and CV group. There were significant differences in the survival rate and peritoneal recurrence rate between the two groups, P<0.05. Intraperitoneal hyperthermic perfusion hemotherapy combined with venoclysis can prevent recurrence and metastasis effectively, and improve the survival patiends with of gastric cancer.